William Blair & Company
ALDX icon

William Blair & Company’s Aldeyra Therapeutics ALDX Stock Holding History

William Blair & Company’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,850
Closed -$45K – 1717
2020
Q2 		$45K Buy
+10,850
New +$39.6K ﹤0.01% 1456

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

William Blair & Company's ALDX Position: Q3 2020 in Review

William Blair & Company sold out of Aldeyra Therapeutics (ALDX) in Q3 2020, closing a stake of 10,850 shares — an estimated $45K sold.

William Blair & Company first reported a position in ALDX in Q2 2020 and held it in 1 quarter. The position peaked at $45K in Q2 2020. 87 funds tracked by Wall St. Rank hold ALDX as of Q3 2020.

  • William Blair & Company reported no remaining Aldeyra Therapeutics position as of Q3 2020 after selling out during the quarter.
  • William Blair & Company sold 10,850 Aldeyra Therapeutics shares in Q3 2020, an estimated $45K.
  • William Blair & Company first reported a position in Aldeyra Therapeutics in Q2 2020 and held it in 1 quarter.
  • William Blair & Company's Aldeyra Therapeutics position peaked at $45K in Q2 2020.
  • 87 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2020.

Based on William Blair & Company's 13F filing for Q3 2020, filed 6 Nov 2020.